Bisphosphonates

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 1, 2003, Pages 253-271

  McClung, Michael R ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; FARNESYL DIPHOSPHATE; FARNESYL PYROPHOSPHATASE; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ALLERGIC REACTION; BONE DENSITY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CONJUNCTIVITIS; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; ESOPHAGUS DISEASE; ESOPHAGUS FUNCTION DISORDER; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; HYPERPHOSPHATEMIA; IRITIS; KIDNEY FAILURE; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRENYLATION; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SPINE FRACTURE; STOMACH ULCER; STRESS FRACTURE; UVEITIS;

EID: 0037299463     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(02)00079-8     Document Type: Review

References (111)

1. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;(Suppl 2):S66-80.
2. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
3. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.
4. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a non-hydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-62.
5. Bergstrom JD, Bostedor RG, Masarachia PJ, et al. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
6. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
7. van Beek E, Pieterman E, Cohen L, et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999;255:491-4.
8. Eriksson E, Frankel VH. Stress risers in bone. Clin Orthop 1985;193:310-2.
9. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fractures in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996;11:1531-8.
10. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002;17:1139-47.
11. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
12. Kanis JA, Gertz BJ, Singer F, et al. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 1995;5:1-13.
13. Chesnut III CH, McClung MR, Ensrud K, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
14. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83:396-402.
15. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after 7 years of treatment. Am J Med 1997;103:468-76.
16. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-15.
17. Heaney RP. The bone remodeling transient: Implications for the interpretation of clinical studies of bone mass changes. J Bone Miner Res 1994;9:1515-23.
18. Hernandez CJ, Beaupre GS, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 2001;29:511-6.
19. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-94.
20. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001;29:185-91.
21. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 2002;166:1426-30.
22. Delmas PD. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000;27:1-3.
23. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999;42:1246-54.
24. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
25. Eastell R, Barton I, Hannon RA, et al. Antifracture efficacy of risedronate: prediction by change in bone resorption markers. J Bone Miner Res 2001;16(Suppl 1):S163.
26. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
27. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med 1998;128:253-61.
28. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000;12:1-12.
29. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348(9041):1535-41.
30. Cummings SR, Black DM, Thompson D, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
31. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997;277:1159-64.
32. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999;9:461-8.
33. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24.
34. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935-42.
35. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000;85:1492-7.
36. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
37. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
38. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results form a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:1895-900.
39. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.
40. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.
41. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
42. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
43. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
44. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-42.
45. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
46. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
47. Cranney A, Welch V, Adachi JD, et al. Etidronate for treating and preventing post-menopausal osteoporosis. Cochrane Database Syst Rev 2001;4:CD003376.
48. Herd RJM, Balena R, Blake GM, et al. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study. Am J Med 1997;103:92-9.
49. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
50. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002;17:1057-64.
51. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
52. Younes H, Farhat G, Fuleihan G el-H. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom 2002;5:143-9.
53. Ravn P, Clemmeson B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study. Bone 1996;19:527-33.
54. Riis BJ, Ise J, von Stein T, et al. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871-8.
55. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307.
56. Recker RR, Stakkestad JA, Felsenberg D, et al. A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial. Osteoporos Int 2000;11(Suppl 2):S209.
57. Cheer SM, Noble S. Zoledronic acid. Drugs 2001;61:799-805.
58. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
59. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98.
60. Mitchell DY, Eusebio RA, Sacco-Gibson NA, et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Parhmacol 2000;40:258-65.
61. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999;12:1152-7.
62. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
63. Lowe CE, Depew WT, Vanner SJ, et al. Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol 2000;95:634-40.
64. Ribeiro A, DeVault KR, Wolfe III JT, et al. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998;47:525-8.
65. Levine J, Nelson D. Esophageal stricture associated with alendronate therapy. Am J Med 1997;102:489-91.
66. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med 2000;160:517-25.
67. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. May Clin Proc 2002;77:262-70.
68. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 2001;13:347-54.
69. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13:515-9.
70. Lenehan TM, Balligand M, Nunamaker DM, et al. Effect of EHDP on fracture healing in dogs. J Orthop Res 1985;3:499-507.
71. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-6.
72. Markowitz GS, Fine PL, D'agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002;39:1118-22.
73. Campisi P, Badhwar V, Morin S, et al. Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case. Dis Colon Rectum 1999;42:1499-501.
74. Jodrell DI, Iveson TJ, Smith IE. Symptomatic hypocalcemia after treatment with highdose aminohydroxypropylidene diphosphonate. Lancet 1987;1:622.
75. Kashyap AS, Kashyap S. Hypoparathyroidism unmasked by alendronate. Postgrad Med J 2000;76:417-8.
76. Recker RR, Hassing GS, Lau JR, et al. The hyperphosphatemic effect of disodium ethane-1-hydroxy-1,1-disphosphonate (EHDP): Renal handling of phosphorous and renal response to parathyroid hormone. J Lab Clin Med 1973;81:258-66.
77. Adami S, Bhalla AK, Dorizzi R, et al. The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
78. Demerjian N, Bolla G, Spreuz A. Severe oral ulcerations induced by alendronate. Clin Rheumatol 1999;18:349-50.
79. Gonzalez-Moles MA, Bagan-Sebastian JV. Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000;29:514-8.
80. Halabe A, Lifschitz BM, Azuri J. Liver damage due to alendronate. N Engl J Med 2000;343:365-6.
81. Kontoleon P, Ilias I, Stavropoulos PG, et al. Urticaria after administration of alendronate. Acta Derm Venereol 2000;80:398.
82. Lazarov A, Moss K, Plosk N, et al. Alendronate-induced lichen planus. Isr Med Assoc J 2002;4:389-90.
83. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994;118:220-4.
84. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999;117:837-8.
85. Ryan PJ, Sampath R. Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford) 2001;40:956-7.
86. Bone HG, Downs RW, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997;82:265-74.
87. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;136:742-6.
88. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000;43:1960-6.
89. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:2166-83.
90. Astrom E, Soderhall S. Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356-64.
91. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
92. Bell NH, Bilezikian JP, Bone 3rd HG, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002;87:2792-7.
93. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int 2000;67:286-90.
94. Lau EM, Woo J, Chan YH, et al. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000;27:677-80.
95. Wasnich RD, Ross PD, Thompson DE, et al. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporos Int 1999;9:455-60.
96. Hodsman AB. Fragility fractures in dialysis and transplant patients. Is it osteoporosis, and how should it be treated? Perit Dial Int 2001;21(Suppl 3):S247-55.
97. Bergner R, Dill K, Boerner D, et al. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002;17:1281-5.
98. Giannini S, Dangel A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-7.
99. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001;12:1530-7.
100. Ikai T, Uematsu M, Eun SS, et al. Prevention of secondary osteoporosis postmenopause in hemiplegia. Am J Phys Med Rehabil 2001;80:169-74.
101. Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999;80:998-1000.
102. Nance PW, Schryvers O, Leslie W, et al. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch Phys Med Rehabil 1999;80:243-51.
103. Bone HG, Greenspan SL, McKeeve, C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720-6.
104. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86:1890-7.
105. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92.
106. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999;84:3076-81.
107. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
108. Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051-5.
109. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34.
110. Stock JL, Bell NH, Chesnut III CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-7.
111. Cosman F, Cummings S, Lindsay R. How long should patients with osteoporosis be treatment with bisphosphonates? J Womens Health Gend Based Med 2000;9:81-4.